Nucleoside analogues: Mechanisms of drug resistance and reversal strategies

Leukemia

Volumn 15, Issue 6, 2001, Pages 875-890

  Galmarini, C M ^a   Mackey, J R ^b   Dumontet, C ^a,c  

^a INSERM   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

5 nucleotidase; Drug resistance; Nucleoside analogues; Nucleoside transporters

Indexed keywords

CLADRIBINE; CYTARABINE; DEOXYADENOSINE DERIVATIVE; FLUDARABINE; GEMCITABINE; GUANINE ARABINOSIDE; NUCLEOSIDE ANALOG; TROXACITABINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELL LEVEL; CONCENTRATION (PARAMETERS); DATA ANALYSIS; DISEASE COURSE; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME INACTIVATION; IN VITRO STUDY; LYMPHOPROLIFERATIVE DISEASE; MEMBRANE TRANSPORT; METABOLISM; MOLECULAR INTERACTION; NEOPLASM; NUCLEOSIDE TRANSPORT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBLICATION; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 0034994444     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402114     Document Type: Review

References (246)

1. New antimetabolites in the treatment of human malignancies
2. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
4. Gemcitabine: Current status of phase I and II trials
5. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies
6. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis
7. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy
8. Long-term survival following cladribine (2-cholorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia
9. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
10. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells
11. Nucleoside transporters: Molecular biology and implications for therapeutic development
12. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line
13. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs
14. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta
15. Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters
16. Nucleoside transport in normal and neoplastic cells
17. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1
18. Functional characterization of a human purine-selective, Na+-dependent nucleoside transporter (hSPNT1) in a mammalian expression system
19. Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair
20. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes
21. Relations between synthesis of deoxyribonucleotides and DNA replication in 3T6 fibroblasts
22. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts
23. Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: Studies with intact cells
24. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis
25. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation
26. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma
27. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside
28. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine
29. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia
30. Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C
31. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine
32. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
33. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA
34. Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells
35. Correlation of cytotoxicity with incorporation of ara-C into DNA
36. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine
37. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: A Leukemia Intergroup study
38. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
39. New antimetabolites in cancer chemotherapy and their clinical impact
40. Gemcitabine in advanced breast cancer
41. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
42. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
43. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
44. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine
45. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity
46. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
47. Induction of apoptosis by gemcitabine
48. Preclinical characteristics of gemcitabine
49. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
50. Cisplatin and gemcitabine in non-small-cell lung cancer
51. Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up
52. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine
53. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: A 5-year survey
54. Membrane transport of 2′-chloro-2′-deoxyadenosine and 2-chloro-2′arabinofluoro-2′-deoxyadenosine is required for cytotoxicity
55. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine
56. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts
57. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes
58. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
59. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells
60. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta
61. Apoptotic death of lymphocytes upon treatment with 2-chloro-2′-deoxyadenosine (2-CdA)
62. Interaction of 2-halogenated dATP analogs (F, CI, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase
63. Metabolism and action of fludarabine phosphate
64. A new mechanism of toxicity of 2-chlorodeoxyadenosine (2CdA)
65. The mechanism of inactivation of S-adenosylhomocysteinase by 2′-deoxyadenosine
66. Selective inhibition of T cell activation by an inhibitor of S-adenosyl- L-homocysteine hydrolase
67. Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms
68. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia
69. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria
70. In vitro transcription of DNA containing 2-chloro-2′-deoxyadenosine monophosphate
71. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway
72. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c
73. 2-Chloro-2′-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function
74. The synthesis of mRNA in isolated mitochondria can be maintained for several hours and is inhibited by high levels of ATP
75. Poly(ADP-ribose) polymerase: A molecular nick-sensor
76. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
77. ADP-ribosylation of proteins. Enzymology and biological significance
78. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes
79. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death
80. Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine
81. The role of nucleoside transport in anticancer drug resistance
82. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
83. Metabolism and action of purine nucleoside analogs
84. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells
85. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity
86. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
87. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia
88. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues
89. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism
90. Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
91. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: In vitro/in vivo correlations
92. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs
93. Mechanisms of resistance to cytarabine in relapsing acute myeloid leukemia (AML) patients
94. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells
95. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
96. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein
97. Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC)
98. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia
99. Deoxycytidine kinase: Properties of the enzyme from human leukemic granulocytes
100. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo
101. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine
102. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells
103. Deoxycytidine kinase is constitutively expressed in human lymphocytes: Consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells
104. Dependence of cell survival on DNA repair in human mononuclear phagocytes
105. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control
106. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases
107. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine
108. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: Substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2′-deoxycytidine
109. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
110. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity
111. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity
112. 2′-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′-deoxyadenosine resistance in lymphoid cell lines
113. Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse
114. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues
115. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: Decreased expression of dCK gene in relapsed leukemia
116. Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia
117. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside
118. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia
119. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine
120. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia
121. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity
122. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene
123. Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia
124. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside
125. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia
126. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo
127. Cloning and expression of human deoxycytidine kinase cDNA
128. Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells
129. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/O and CCRF/CEM/dCk-1
130. Cytosine arabinoside triphosphate production in human leukaemic myeloblasts: Interactions with deoxycytidine
131. Mammalian deoxyribonucleoside kinases
132. Cloning and characterization of mouse deoxyguanosine kinase. Evidence for a cytoplasmic isoform
133. Cloning and expression of human deoxyguanosine kinase cDNA
134. Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2
135. Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA
136. Human thymidine kinase 2: Molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates
137. Ecto-enzyme and signaling functions of lymphocyte CD73
138. Expression of 5′-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage
139. Regulation of low Km (ecto-) 5′-nucleotidase gene expression in leukemic cells
140. Human high-Km 5′-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells
141. Mammalian 5′(3′)-deoxyribonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells
142. Evidence for 'low Km' and 'high Km' soluble 5′-nucleotidases in human tissues and rat liver
143. Altered properties of human T-lymphoblast soluble low Km 5′-nucleotidase: Comparison with B-lymphoblast enzyme
144. Expression of cytoplasmic 5′-nucleotidase in leukemic blasts is an adverse prognostic factor in AML patients treated with cytarabine
145. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line
146. Human cytidine deaminase: Purification of enzyme, cloning, and expression of its complementary DNA
147. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine
148. Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity
149. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine
150. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells
151. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro
152. Cytidine deaminase and the development of resistance to arabinosyl cytosine
153. Activity of thymidine kinase and of polymerase alpha, as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia
154. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia
155. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro
156. Ara-C metabolism: Implications for drug resistance and drug interactions
157. Regulation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate
158. Mutagenesis and deoxyribonucleotide pool imbalance
159. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells
160. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta
161. S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs
162. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate
163. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
164. Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5′-triphosphate
165. Comparative effects of the 5′-triphosphates of 9-beta-(2′-azido-2′-deoxy-D-arabinofuranosyl)adenine and 9-beta-D-arabinofuranosyladenine on DNA polymerases from L1210 leukemia cells
166. Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5′-triphosphate
167. Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in P388 murine leukemic cells resistant to vincristine
168. Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia
169. Bcl-2 and the regulation of programmed cell death
170. Identification of a p53-dependent negative response element in the bcl-2 gene
171. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
172. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells
173. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine
174. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
175. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
176. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia
177. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
178. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis
179. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the chemotherapy
180. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
181. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
182. In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis
183. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance
184. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX
185. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues - Correlation with clinical course
186. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine
187. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: Correlation with in vitro sensitivity to chlorambucil and purine analogs
188. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage
189. Pharmacologically directed ara-C therapy for refractory leukemia
190. Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2′-deoxyadenosine (Cladribine) in human lymphocytes
191. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity
192. Activation of deoxycytidine kinase during inhibition of DNA synthesis in human lymphocytes
193. Activation of deoxycytidine kinase by various nucleoside analogues
194. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
195. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia
196. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia
197. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy
198. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
199. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: Clinical efficacy and modulation of arabinosylcytosine pharmacology
200. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule
201. Clinical experience with fludarabine in leukaemia
202. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias
203. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells
204. Pharmacokinetics of arabinosylguanine (ara-G) and its triphosphate (ara-GTP) during a phase I trial of compound GW506U in refractory hematological malignancies: Correlation with response
205. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells
206. Increase in Ara-C sensitivity in Ara-C-sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway
207. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D-arabinofuranosylcytosine in highly resistant human leukemia cells
208. Biochemical modulation of arabinosylcytosine for therapy of leukemias
209. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions
210. Cytarabine and neurologic toxicity
211. Neurotoxicity of purine analogs: A review
212. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): Association with increased ratios of dCK/5′-NT and Bax/Bcl-2
213. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine
214. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
215. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture
216. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: A model for leukemia chemotherapy
217. Nucleoside transport in acute leukaemia and lymphoma: Close relation to proliferative rate
218. Multiple myeloma: Expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation
219. Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter
220. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor
221. Improved prognosis in mice with advanced myeloid leukemia following administration of GM-CSF and cytosine arabinoside
222. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia
223. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group
224. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
225. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair
226. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine
227. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia
228. The expanding role of fludarabine in hematologic malignancies
229. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma
230. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
231. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
232. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine
233. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
234. Combination therapy with gemcitabine in non-small cell lung cancer
235. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration
236. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells
237. Potent anti-tumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models
238. Troxacitabine, (BCH-4556), a novel dioxolane nucleoside analog, has anti-leukemic activity
239. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells
240. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: A case report and review of the literature
241. A phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five-day schedule in children and adults with refractory hematologic malignancies
242. Transport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells
243. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice
244. Cytoplasmic 5′(3′)-nucleotidase from human placenta
245. Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form
246. 5′-Nucleotidase: Molecular structure and functional aspects